Cargando…

Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

OBJECTIVE: To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy. RESEARCH DESIGN AND METHODS: Patients (n = 368; A1C ≥7%) were randomized to 20 mg/day rimonabant or placebo in this 48-week...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hollander, Priscilla A., Amod, Aslam, Litwak, León E., Chaudhari, Umesh
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827517/ https://www.ncbi.nlm.nih.gov/pubmed/20009090 http://dx.doi.org/10.2337/dc09-0455

Ejemplares similares

SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients : Effects of monotherapy with rimonabant, the first selective CB(1) receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2008)

Rimonabant for treating tobacco dependence
por: Steinberg, Michael B, et al.
Publicado: (2007)

Arpeggio: A Web Server for Calculating and Visualising Interatomic Interactions in Protein Structures
por: Jubb, Harry C, et al.
Publicado: (2017)

ARPEGGIO: Automated Reproducible Polyploid EpiGenetic GuIdance workflOw
por: Milosavljevic, Stefan, et al.
Publicado: (2021)

Rimonabant: From RIO to Ban
por: Sam, Amir H., et al.
Publicado: (2011)

Rimonabant, Gastrointestinal Motility and Obesity
por: Sun, Yan, et al.
Publicado: (2012)

Rimonabant-induced depression in schizophrenia
por: Arasappa, Rashmi, et al.
Publicado: (2014)

The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
por: Murro, Ada Letícia B
Publicado: (2009)

Arpeggio: harmonic compression of ChIP-seq data reveals protein-chromatin interaction signatures
por: Stanton, Kelly Patrick, et al.
Publicado: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander, Priscilla A
Publicado: (2012)

Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome
por: Waterlow, Mark, et al.
Publicado: (2007)

Potential Implications of Rimonabant on Age-Related Oxidative Stress and Inflammation
por: Szabó, Renáta, et al.
Publicado: (2022)

Reduced Food Intake is the Major Contributor to the Protective Effect of Rimonabant on Islet in Established Obesity-Associated Type 2 Diabetes
por: Jin, Sang-Man, et al.
Publicado: (2013)

Different Transcriptional Control of Metabolism and Extracellular Matrix in Visceral and Subcutaneous Fat of Obese and Rimonabant Treated Mice
por: Poussin, Carine, et al.
Publicado: (2008)

Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results
por: Fernández-Fernández, Cristina, et al.
Publicado: (2014)

Can antidepressants unlock prescription of rimonabant in the fight against COVID-19?
por: Salles, Juliette, et al.
Publicado: (2021)

Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes
por: Lauffenburger, Julie C., et al.
Publicado: (2020)

Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease
por: Jorgačević, Bojan, et al.
Publicado: (2015)

Rimonabant and Cannabidiol Rewrite the Interactions between Breast Cancer Cells and Tumor Microenvironment
por: Proto, Maria Chiara, et al.
Publicado: (2023)

Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion
por: Aschner, Pablo, et al.
Publicado: (2021)

Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China
por: Liu, Guangxu, et al.
Publicado: (2018)

The Gut Microbiota Profile According to Glycemic Control in Type 1 Diabetes Patients Treated with Personal Insulin Pumps
por: Mrozinska, Sandra, et al.
Publicado: (2021)

RP-HPLC Method Development and Its Validation for Quantitative Determination of Rimonabant in Human Plasma
por: Bankey, Shravan, et al.
Publicado: (2012)

Hepatic targeting of the centrally active cannabinoid 1 receptor (CB(1)R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes
por: Hirsch, Shira, et al.
Publicado: (2023)

Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes
por: Henao-Carrillo, Diana Cristina, et al.
Publicado: (2018)

Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory
por: Yonamine, Caio Yogi, et al.
Publicado: (2016)

Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics
por: Arshad, Rabia, et al.
Publicado: (2017)

Co-administration of rimonabant prevents glucose intolerance in Sprague-Dawley rats treated chronically with lopinavir/ritonavir and zidovudine: an experimental study design
por: Makamu, Brian Lishenga, et al.
Publicado: (2023)

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
por: Meininger, Gary E., et al.
Publicado: (2011)

Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study
por: Davis, Georgia, et al.
Publicado: (2022)

Effects of the cannabinoid CB(1) receptor antagonist rimonabant on distinct measures of impulsive behavior in rats
por: Pattij, Tommy, et al.
Publicado: (2007)

Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids
por: Fiore, Donatella, et al.
Publicado: (2018)

Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant
por: Heppenstall, Charlotte, et al.
Publicado: (2012)

Insulin Injection Technique is Associated with Glycemic Variability in Patients with Type 2 Diabetes
por: Yuan, Lu, et al.
Publicado: (2018)

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100
por: Hollander, Priscilla A., et al.
Publicado: (2019)

Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes: A randomized controlled trial
por: Logtenberg, Susan J., et al.
Publicado: (2009)

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
por: Mathieu, Chantal, et al.
Publicado: (2013)

The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin*
por: Tan, Florence Hui Sieng, et al.
Publicado: (2021)

Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology
por: Chavez-Tapia, Norberto C, et al.
Publicado: (2009)

Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice
por: Hu, Chunxiu, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5m5hrs4huc4e2c9n0sl10mav0j